Concepts and Terms for Addressing Disparities in Public Health Emergencies: Accounting for the COVID-19 Pandemic and the Social Determinants of Health in the United States.

Public health emergencies, including the coronavirus disease 2019 (COVID-19) pandemic, highlight disproportionate impacts faced by populations with existing disparities. Concepts and terms used to describe populations disproportionately impacted in emergencies vary over time and across disciplines, but United States (US) federal guidance and law require equal access to our nation's emergency resources. At all levels of emergency planning, public health and their partners must be accountable to populations with existing inequities, which requires a conceptual shift toward using the data-driven social determinants of health (SDOH).

Assessment of the patient who failed treatment for chronic hepatitis C.

Chronic hepatitis C virus (HCV) infection affects more than 4 million people in the United States and 170 million people in the world, making it a major public health problem. Currently, about one half of the patients undergoing hepatitis C treatment do not experience a sustained viral response. With time, this high nonresponse rate has created a large pool of such patients (nonresponders), many of whom have advanced fibrosis or cirrhosis.

Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis.

To elucidate the hematopoietic activity of recombinant human interleukin-11 (rhIL-11, [Neumega, Cambridge, MA]) in patients with cirrhosis and thrombocytopenia, we administered rhIL-11 at 50 microg/kg/d subcutaneously to 10 patients for 10 days with a 30-day follow-up period. All treated patients (n = 9) experienced a gradual, yet significant increase in their platelet count above the baseline value (P < or =.01) reaching the peak value (median, 93,000/microL; range, 60,000-206,000/microL) at a median of 13 days (range, 6-23 days).